Vimarsana
Biggest News Aggregation in the World

Page 11 - Restated Listing Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Restated Listing Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Restated Listing Statement Today - Breaking & Trending Today

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre - Vimarsana News

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre

Share this article Share this article International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants TORONTO, June 9, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BR...

Braxia Scientific Appoints Dr. David Greenberg to Board of Directors - Vimarsana News

Braxia Scientific Appoints Dr. David Greenberg to Board of Directors

/PRNewswire/ - Braxia Scientific Corp. (the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing...

Braxia Scientific Announces Symbol Change on OTC Markets to "BRAXF" - Vimarsana News

Braxia Scientific Announces Symbol Change on OTC Markets to "BRAXF"

Braxia Scientific Corp. a research driven clinical platform developing and providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce its common shares, previously listed for trading on the OTC Market in the United States under the symbol “SHRMF”, are to commence trading on the OTC Market under the symbol “BRAXF” effective May 21, 2021 . The Company’s common shares …  Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (OTC: SHRMF) (FWB: 496), a research driven clinical platform developing and providing novel ketamine treatm...

Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants - Vimarsana News

Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants

Share this article Share this article Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia's Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and psychedelic treatment TORONTO, May 20, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific" or the "Company"), (CSE: BRAX) (F...

Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants - Vimarsana News

Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants

Over 200 physicians and healthcare providers from Canada U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and … Over 200 physicians and healthcare providers from Canada , U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esket...